These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32010121)

  • 1. Immune and Neuroendocrine Trait and State Markers in Psychotic Illness: Decreased Kynurenines Marking Psychotic Exacerbations.
    De Picker L; Fransen E; Coppens V; Timmers M; de Boer P; Oberacher H; Fuchs D; Verkerk R; Sabbe B; Morrens M
    Front Immunol; 2019; 10():2971. PubMed ID: 32010121
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.
    Szymona K; Zdzisińska B; Karakuła-Juchnowicz H; Kocki T; Kandefer-Szerszeń M; Flis M; Rosa W; Urbańska EM
    Neurotox Res; 2017 Jul; 32(1):17-26. PubMed ID: 28275903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tryptophan, kynurenine, and kynurenine metabolites: Relationship to lifetime aggression and inflammatory markers in human subjects.
    Coccaro EF; Lee R; Fanning JR; Fuchs D; Goiny M; Erhardt S; Christensen K; Brundin L; Coussons-Read M
    Psychoneuroendocrinology; 2016 Sep; 71():189-96. PubMed ID: 27318828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise and the Kynurenine pathway: Current state of knowledge and results from a randomized cross-over study comparing acute effects of endurance and resistance training.
    Joisten N; Kummerhoff F; Koliamitra C; Schenk A; Walzik D; Hardt L; Knoop A; Thevis M; Kiesl D; Metcalfe AJ; Bloch W; Zimmer P
    Exerc Immunol Rev; 2020; 26():24-42. PubMed ID: 32139353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.
    Raison CL; Dantzer R; Kelley KW; Lawson MA; Woolwine BJ; Vogt G; Spivey JR; Saito K; Miller AH
    Mol Psychiatry; 2010 Apr; 15(4):393-403. PubMed ID: 19918244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum kynurenic acid is reduced in affective psychosis.
    Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
    Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kynurenine Pathway in Autism Spectrum Disorders in Children.
    Bryn V; Verkerk R; Skjeldal OH; Saugstad OD; Ormstad H
    Neuropsychobiology; 2017; 76(2):82-88. PubMed ID: 29694960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease.
    Pawlak K; Brzosko S; Mysliwiec M; Pawlak D
    Atherosclerosis; 2009 Jun; 204(2):561-6. PubMed ID: 19027117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hypertrophic but not maximal strength loading transiently enhances the kynurenine pathway towards kynurenic acid.
    Joisten N; Schumann M; Schenk A; Walzik D; Freitag N; Knoop A; Thevis M; Bloch W; Zimmer P
    Eur J Appl Physiol; 2020 Jun; 120(6):1429-1436. PubMed ID: 32306154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
    Young KD; Drevets WC; Dantzer R; Teague TK; Bodurka J; Savitz J
    Brain Behav Immun; 2016 Aug; 56():335-42. PubMed ID: 27091600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis.
    Curto M; Lionetto L; Fazio F; Corigliano V; Comparelli A; Ferracuti S; Simmaco M; Nicoletti F; Baldessarini RJ
    Schizophr Res; 2019 Jun; 208():465-466. PubMed ID: 30837204
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.
    Chiappelli J; Notarangelo FM; Pocivavsek A; Thomas MAR; Rowland LM; Schwarcz R; Hong LE
    Neuropsychopharmacology; 2018 Jul; 43(8):1675-1680. PubMed ID: 29520060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
    Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
    PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does escitalopram reduce neurotoxicity in major depression?
    Halaris A; Myint AM; Savant V; Meresh E; Lim E; Guillemin G; Hoppensteadt D; Fareed J; Sinacore J
    J Psychiatr Res; 2015; 66-67():118-26. PubMed ID: 26009299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
    Savitz J; Drevets WC; Smith CM; Victor TA; Wurfel BE; Bellgowan PS; Bodurka J; Teague TK; Dantzer R
    Neuropsychopharmacology; 2015 Jan; 40(2):463-71. PubMed ID: 25074636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
    Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
    Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State-associated changes in longitudinal [
    De Picker L; Ottoy J; Verhaeghe J; Deleye S; Wyffels L; Fransen E; Kosten L; Sabbe B; Coppens V; Timmers M; de Boer P; Van Nueten L; Op De Beeck K; Oberacher H; Vanhoenacker F; Ceyssens S; Stroobants S; Staelens S; Morrens M
    Brain Behav Immun; 2019 Mar; 77():46-54. PubMed ID: 30503836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kynurenine and its metabolites in Alzheimer's disease patients.
    Gulaj E; Pawlak K; Bien B; Pawlak D
    Adv Med Sci; 2010; 55(2):204-11. PubMed ID: 20639188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.
    Condray R; Dougherty GG; Keshavan MS; Reddy RD; Haas GL; Montrose DM; Matson WR; McEvoy J; Kaddurah-Daouk R; Yao JK
    Int J Neuropsychopharmacol; 2011 Jul; 14(6):756-67. PubMed ID: 21275080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.
    Myint AM; Schwarz MJ; Verkerk R; Mueller HH; Zach J; Scharpé S; Steinbusch HW; Leonard BE; Kim YK
    Brain Behav Immun; 2011 Nov; 25(8):1576-81. PubMed ID: 21620952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.